Karageorgopoulos, DE, Falagas, ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis
Bergogne-Berezin, E, Towner, KJ.
Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev
Landman, D, Quale, JM, Mayorga, D, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: the preantibiotic era has returned. Arch Intern Med
Fournier, PE, Richet, H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis
Brown, J, Doloresco Iii, F, Mylotte, JM. “Never events”: not every hospital-acquired infection is preventable. Clin Infect Dis
Umscheid, CA, Mitchell, MD, Doshi, JA, Agarwal, R, Williams, K, Brennan, PJ. Estimating the proportion of healthcare-associated infections that are reasonably preventable and the related mortality and costs. Infect Control Hosp Epidemiol
Zimlichman, E, Henderson, D, Tamir, O, et al. Health care-associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med
Gabriel, L, Beriot-Mathiot, A. Hospitalization stay and costs attributable to Clostridium difficile infection: a critical review. J Hosp Infect
Nanwa, N, Kendzerska, T, Krahn, M, et al. The economic impact of Clostridium difficile infection: a systematic review. Am J Gastroenterol
Wilson, SJ, Knipe, CJ, Zieger, MJ, et al. Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. Am J Infect Control
Grupper, M, Sprecher, H, Mashiach, T, Finkelstein, R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol
Playford, EG, Craig, JC, Iredell, JR. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect
Sunenshine, RH, Wright, MO, Maragakis, LL, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis
Weingarten, CM, Rybak, MJ, Jahns, BE, Stevenson, JG, Brown, WJ, Levine, DP. Evaluation of Acinetobacter baumannii infection and colonization, and antimicrobial treatment patterns in an urban teaching hospital. Pharmacotherapy
Wong, TH, Tan, BH, Ling, ML, Song, C. Multi-resistant Acinetobacter baumannii on a burns unit—clinical risk factors and prognosis. Burns
Nelson, RE, Nelson, SD, Khader, K, et al. The magnitude of time-dependent bias in the estimation of excess length of stay attributable to healthcare-associated infections. Infect Control Hosp Epidemiol
Ababneh, M, Harpe, S, Oinonen, M, Polk, RE. Trends in aminoglycoside use and gentamicin-resistant gram-negative clinical isolates in US academic medical centers: implications for antimicrobial stewardship. Infect Control Hosp Epidemiol
Landman, D, Babu, E, Shah, N, et al. Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration. J Antimicrob Chemother
Reddy, T, Chopra, T, Marchaim, D, et al. Trends in antimicrobial resistance of Acinetobacter baumannii isolates from a metropolitan Detroit health system. Antimicrob Agents Chemother
Hall, MJ, Levant, S, DeFrances, CJ. Trends in Inpatient Hospital Deaths: National Hospital Discharge Survey, 2000-2010. Hyattsville, MD: National Center for Health Statistics; 2013.
Nelson, RE, Jones, M, Liu, CF, et al. The impact of healthcare-associated methicillin-resistant Staphylococcus aureus infections on post-discharge healthcare costs and utilization. Infect Control Hosp Epidemiol
Nelson, RE, Stevens, VW, Jones, M, Samore, MH, Rubin, MA. Health care-associated methicillin-resistant Staphylococcus aureus infections increases the risk of postdischarge mortality. Am J Infect Control
Manchanda, V, Sanchaita, S, Singh, N. Multidrug resistant Acinetobacter. J Glob
Chastek, B, Harley, C, Kallich, J, Newcomer, L, Paoli, CJ, Teitelbaum, AH. Health care costs for patients with cancer at the end of life. J Oncol Pract
Kelley, AS, McGarry, K, Fahle, S, Marshall, SM, Du, Q, Skinner, JS. Out-of-pocket spending in the last five years of life. J Gen Intern Med
Riley, GF, Lubitz, JD. Long-term trends in Medicare payments in the last year of life. Health Serv Res
Teno, JM, Gozalo, PL, Bynum, JP, et al. Change in end-of-life care for Medicare beneficiaries: site of death, place of care, and health care transitions in 2000, 2005, and 2009. JAMA
Rice, DP. Cost of illness studies: what is good about them?
Clabaugh, G, Ward, MM. Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost. Value Health
Finkelstein, E, Corso, P. Cost-of-illness analyses for policy making: a cautionary tale of use and misuse. Expert Rev Pharmacoecon Outcomes Res
Rice, DP. Cost-of-illness studies: fact or fiction?
Larg, A, Moss, JR. Cost-of-illness studies: a guide to critical evaluation. PharmacoEconomics
Graves, N, Harbarth, S, Beyersmann, J, Barnett, A, Halton, K, Cooper, B. Estimating the cost of health care-associated infections: mind your p’s and q’s. Clin Infect Dis
Paterson, DL, Harris, PN. The new Acinetobacter equation: hypervirulence plus antibiotic resistance equals big trouble. Clin Infect Dis
Jones, CL, Clancy, M, Honnold, C, et al. Fatal outbreak of an emerging clone of extensively drug-resistant Acinetobacter baumannii with enhanced virulence. Clin Infect Dis
Centers for Disease Control and Prevention (CDC). Antibiotic Resistance Threats in the United States, 2013. Atlanta, GA: CDC; 2013.